All these data allow us to hypothesize that, in NSCLC, ACSL3 overexpression is defining a metabolic scenario, associated with increased fatty acids activation conducting to an aggressive and invasive tumor cell and consequently with poor patient survival. The gene discussed is ACSL3; the disease is non-small cell lung carcinoma.